The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2025 RFP: Data Advice To Action - DATA-PD, 2026Blood-based Signatures of CSF Synuclein SAA Positivity
Study Rationale:
The ability to identify people during life, who are likely to have underlying Lewy body pathology has been a game-changer. However, the current test (SAA) is limited...
-
Research Grant, 2026From Functional Maps to Clinical Outcomes: Interpreting GBA1 Variant Effects in Parkinson's Disease
Study Rationale:
Genetic variants in the GBA1 gene are among the most important risk factors for Parkinson’s disease. GBA1 encodes an enzyme that breaks down waste inside lysosomes...
-
Bridge Funding for Disrupted Neurodegenerative Research Grant Program, 2026Region-specific Effects of Pathology and Vocal Training
Study Rationale:
Voice and communication deficits are common in Parkinson’s disease. They occur early in the disease process, are progressive in nature, and significantly impact...
-
Research Grant, 2026Disease Modeling for Neuronal Alpha-synuclein Diseases
Neuronal alpha-synuclein diseases (NSD), such as Parkinson’s disease, progress slowly and affect people differently, making it hard to predict when symptoms will appear or worsen. Current methods for...
-
Summer 2023 RFP: Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program - Biology, 2026Characterization of Constrained Peptides Targeting LRRK2 and Downstream Signaling
Study Rationale:
Genetic mutations in LRRK2 are linked to familial Parkinson’s, however, there are currently no clinically approved inhibitors for LRRK2. In this study, we will...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Characterization of a Novel Strategy to Target LRRK2 and Its Downstream Signaling Pathway
Study Rationale: Genetic mutations that activate LRRK2 are linked to familial Parkinson’s disease (PD). However, no clinically approved inhibitors for LRRK2 currently exist. In this study, we will...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.